OncoMatch

OncoMatch/Clinical Trials/NCT06555003

DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases

Is NCT06555003 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Drug-Eluting Embolic Bead and Chemotherapy drug for liver neoplasm.

Phase 3RecruitingTehran University of Medical SciencesNCT06555003Data as of Jun 2026Location: Iran

Treatment: Drug-Eluting Embolic Bead · Chemotherapy drugA total of 116 patients who meet the inclusion criteria and are chemotherapy-naïve for their metastatic disease, will be randomly assigned to either the treatment group (DEBIRI plus systemic chemotherapy) or the control group (systemic chemotherapy alone). After 4 cycles of chemotherapy and 2 cycles of DEBIRI, patient reassessment to evaluate treatment response, based on RECIST criteria, will be performed using MRI or CT scan within 1-3 months of treatment initiation. The feasibility of secondary tumor resection, as primary endpoint, will be reassessed at a three-month follow-up multidisciplinary team (MDT) meeting, guided by established clinical guidelines.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Drug-Eluting Embolic BeadChemotherapy drug

Cancer type

Colorectal Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Blood counts

absolute neutrophil count ≥ 1.5 × 10^9/l, platelet ≥ 75 ×10^9/l, international normalized ratio ≤ 1.3

Kidney function

creatinine ≤ 2.0 mg/dl

Liver function

total bilirubin ≤ 2.0 mg/dl, aspartate aminotransferase and alanine aminotransferase ≤ 5 × uln, albumin ≥ 2.5 g/dl

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06555003 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify